Lantheus Sale Scrutinized Over Shareholder Value Concerns
Event summary
- Halper Sadeh LLC is investigating Lantheus' $102.50 per share sale to Curium, plus up to $12 in contingent value rights.
- The law firm questions whether Lantheus obtained the best price and conducted a fair process.
- Investigation focuses on potential fiduciary duty breaches by Lantheus' board.
- Contingent Value Rights tied to commercial milestones through 2030.
The big picture
This investigation highlights growing scrutiny of board decisions in mid-sized biotech acquisitions, particularly when contingent value rights complicate valuation assessments. The case may test how aggressively investor rights firms pursue governance claims in deals below $1 billion where financial advisors have less incentive to challenge pricing.
What we're watching
- Governance Dynamics
- How the investigation may impact Lantheus' board composition and future dealmaking.
- Valuation Scrutiny
- Whether $102.50 per share represents fair value given potential milestone payouts.
- Regulatory Impact
- The pace at which similar investigations emerge in healthcare M&A amid rising shareholder activism.
Related topics